CollPlant Biotechnologies (CLGN) Non-Current Debt (2017)
CollPlant Biotechnologies (CLGN) posted Non-Current Debt of $3.6 million for Q4 2017.
CollPlant Biotechnologies (CLGN) Non-Current Debt (2017) Analysis & Trends
CollPlant Biotechnologies' Non-Current Debt history runs 1 years deep, the most recent figure standing at $3.6 million for Q4 2017.
- Quarterly Non-Current Debt changed N/A year-over-year to $3.6 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $3.6 million (changed N/A YoY) and the FY2017 annual result came in at $3.6 million, changed N/A from the prior year.
- Non-Current Debt was $3.6 million for Q4 2017 at CollPlant Biotechnologies.
- Across five years, Non-Current Debt topped out at $3.6 million in Q4 2017 and bottomed at $3.6 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,913.26 Bn | 1,913.20 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.02 Bn | 466.23 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 122.17 Bn | 114.92 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.10 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.60 Bn | 50.42 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.39 Bn | 34.38 Bn | 959.66 Mn | - |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 3.65 Mn |